These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8648206)

  • 21. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
    Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
    Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reactogenicity, safety, immunogenicity and prophylactic effectiveness of polysaccharide pneumococcus vaccine during immunization of HIV-infected patients].
    Fel'dblium IV; Nikolenko VV; Vorob'eva NN; Ivanova ÉS; Shmagel' NG; Khafizov KM; Iurganova GA; Zverev SIa
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (3):52-60. PubMed ID: 24000594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of pneumococcal vaccine in heart transplant recipients.
    Blumberg EA; Brozena SC; Stutman P; Wood D; Phan HM; Musher DM
    Clin Infect Dis; 2001 Jan; 32(2):307-10. PubMed ID: 11170924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination.
    Musher DM; Groover JE; Rowland JM; Watson DA; Struewing JB; Baughn RE; Mufson MA
    Clin Infect Dis; 1993 Jul; 17(1):66-73. PubMed ID: 8353248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
    Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
    Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations.
    Kroon FP; van Dissel JT; Ravensbergen E; Nibbering PH; van Furth R
    Vaccine; 1999 Oct; 18(5-6):524-30. PubMed ID: 10519943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults.
    Gordon SB; Miller DE; Day RB; Ferry T; Wilkes DS; Schnizlein-Bick CT; Zijlstra EE; Read RC; Molyneux ME; Twigg HL
    J Infect Dis; 2003 Sep; 188(5):666-70. PubMed ID: 12934182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children.
    Ditse Z; Adrian PV; Kuwanda L; Madhi SA
    Vaccine; 2013 Sep; 31(40):4421-7. PubMed ID: 23845819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons.
    Chang Q; Abadi J; Alpert P; Pirofski L
    J Infect Dis; 2000 Apr; 181(4):1313-21. PubMed ID: 10762563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease.
    Vandenbruaene M; Colebunders R; Mascart-Lemone F; Haerden Y; Van Hove D; Peeters M; Goeman J; Van Royen P; Avonts D
    J Infect Dis; 1995 Aug; 172(2):551-3. PubMed ID: 7622903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.
    Rubins JB; Alter M; Loch J; Janoff EN
    Infect Immun; 1999 Nov; 67(11):5979-84. PubMed ID: 10531257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.
    Hilleman MR; Carlson AJ; McLean AA; Vella PP; Weibel RE; Woodhour AF
    Rev Infect Dis; 1981; 3 Suppl():S31-42. PubMed ID: 7025159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focusing on Good Responders to Pneumococcal Polysaccharide Vaccination in General Hospital Patients Suspected for Immunodeficiency. A Decision Tree Based on the 23-Valent Pneumococcal IgG Assay.
    Janssen LMA; Heron M; Murk JL; Leenders ACAP; Rijkers GT; de Vries E
    Front Immunol; 2019; 10():2496. PubMed ID: 31749801
    [No Abstract]   [Full Text] [Related]  

  • 37. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies.
    Lue C; Tarkowski A; Mestecky J
    J Immunol; 1988 Jun; 140(11):3793-800. PubMed ID: 3372993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
    French N; Moore M; Haikala R; Kayhty H; Gilks CF
    J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.
    Konradsen HB
    Clin Infect Dis; 1995 Sep; 21(3):616-20. PubMed ID: 8527553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
    J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.